These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35150777)

  • 1. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned.
    Can I; Cox MJ; Siegler EL; Sakemura R; Kenderian SS
    Exp Hematol; 2022 Apr; 108():1-7. PubMed ID: 35150777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
    Cox MJ; Lucien F; Sakemura R; Boysen JC; Kim Y; Horvei P; Manriquez Roman C; Hansen MJ; Tapper EE; Siegler EL; Forsman C; Crotts SB; Schick KJ; Hefazi M; Ruff MW; Can I; Adada M; Bezerra E; Kankeu Fonkoua LA; Nevala WK; Braggio E; Ding W; Parikh SA; Kay NE; Kenderian SS
    Mol Ther; 2021 Apr; 29(4):1529-1540. PubMed ID: 33388419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies.
    Borogovac A; Siddiqi T
    Semin Hematol; 2024 Apr; 61(2):119-130. PubMed ID: 38290860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
    Bair SM; Porter DL
    Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
    Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
    Fraietta JA; Schwab RD; Maus MV
    Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
    Sun W; Liang AB; Huang H; Huang XJ
    Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.
    Zou Y; Xu W; Li J
    J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia: Are We Any Closer to a Cure?
    Rhodes JM; Schuster SJ
    Cancer J; 2019; 25(6):436-441. PubMed ID: 31764125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.
    Todorovic Z; Todorovic D; Markovic V; Ladjevac N; Zdravkovic N; Djurdjevic P; Arsenijevic N; Milovanovic M; Arsenijevic A; Milovanovic J
    Curr Oncol; 2022 May; 29(5):3647-3657. PubMed ID: 35621683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia.
    Hamieh M; Sadelain M
    Trends Mol Med; 2018 Sep; 24(9):729-731. PubMed ID: 30149852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies.
    Liao YM; Hsu SH; Chiou SS
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular Therapy in Chronic Lymphocytic Leukemia: Have We Advanced in the Last Decade?
    Katz OB; Yehudai-Ofir D; Zuckerman T
    Acta Haematol; 2024; 147(1):99-112. PubMed ID: 37812926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer.
    Mavi AK; Gaur S; Gaur G; Babita ; Kumar N; Kumar U
    Cell Signal; 2023 May; 105():110638. PubMed ID: 36822565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular Immunotherapy in B-Cell Malignancy.
    Schwarzbich MA; Witzens-Harig M
    Oncol Res Treat; 2017; 40(11):674-681. PubMed ID: 29065420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells.
    Yang S; Huang X; Gale RP
    Blood Rev; 2022 Jan; 51():100884. PubMed ID: 34489116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.